Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

242 - Targeted Anticancer Therapy and Concomitant Hypofractionated Radiotherapy in Breast Cancer

Date

05 Mar 2018

Session

Poster display

Presenters

Elisabetta Bonzano

Citation

Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047

Authors

E. Bonzano, M. Guenzi, R. Corvò

Author affiliations

  • Radiation Oncology, IRCCS Policlinico San Martino and University, 16132 - Genova/IT
More

Resources

Abstract 242

HER-2 positive breast cancer represents 20% of breast cancers. If untreated, they have a worse prognosis than HER-2-negative tumors, but adjuvant therapy with trastuzumab (TSZ) improves survival. This treatment is usually well tolerated. The more frequent adverse event (30%) is asymptomatic decrease in left ventricular ejection fraction (LVEF), evaluated in our experience by echocardiogram at the start and the end of TSZ.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings